Previous 10 | Next 10 |
CAMBRIDGE, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will pa...
CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will pr...
Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks rallied Friday, led by technology and communication services, but the major averages finished lower for the week on escalating inflati...
Gainers: Altamira (NASDAQ:CYTO) +68%. Wunong (NASDAQ:WNW) +52%. Everspin Technologies (NASDAQ:MRAM) +44%. SOC Telemed (NASDAQ:TLMD) +33%. Bit Brother (NASDAQ:BTB) +31%. Kura Sushi USA (NASDAQ:KRUS) +27%. Brilliant Earth Group (NASDAQ:BRLT) +26%. Xponential Fitness (NYSE:XPOF) +23%....
Shares of Oncorus (NASDAQ: ONCR) were crashing 44.7% lower at 11:11 a.m. EST on Friday. The big decline came after the drugmaker announced initial data from its ongoing phase 1 clinical study evaluating experimental immunotherapy ONCR-177 in treating patients with solid tumors. ...
Gainers: Altamira Therapeutics (NASDAQ:CYTO) +82%, SOC Telemed (NASDAQ:TLMD) +16%, Sundial Growers (NASDAQ:SNDL) +16%, Beyond Air (NASDAQ:XAIR) +15%, IM Cannabis (NASDAQ:IMCC) +13%. Losers: Oncorus (NASDAQ:ONCR) -43%, Acutus Medical (NASD...
Oncorus (ONCR -41.3%) shares have extended the pre-market slump after the company reported initial data for its investigational cancer therapy ONCR-177 from an ongoing open-label Phase 1 trial in heavily pretreated patients with advanced, injectable solid tumors. In the dose-escalation portio...
ONCR-177 was well tolerated with no dose-limiting toxicities in the surface lesion dose escalation part of the first-in-human study in heavily pretreated patients with advanced, injectable solid tumors Recommended Phase 2 dose (RP2D) selected and expansion monotherapy cohort dosing is...
Oncorus (NASDAQ:ONCR) will gain access to the use of locally delivered Interleukin-12 (IL-12) via oncolytic viral expression through a licensing agreement with Gaeta Therapeutics. The IL-12 is intended to be used in combination with immune checkpoint inhibitors, including CTLA-4, PD-1 or PD-L...
CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that it has signed an exclusive licensing agreement with Gaeta Therapeutics Ltd., relate...
News, Short Squeeze, Breakout and More Instantly...
iClick Interactive Asia Group Limited (ICLK) is expected to report for quarter end 2023-09-30 Applied Minerals Inc (AMNL) is expected to report for quarter end 2023-09-30 Banco Do Brasil S.A. ADR (BDORY) is expected to report for Q3 2023 Rubius Therapeutics Inc. (RUBY) is expected to ...
American Bio Medica Corp. (ABMC) is expected to report for quarter end 2023-09-30 Surgalign Holdings Inc. (SRGAQ) is expected to report for quarter end 2023-09-30 MillerKnoll Inc. (MLKN) is expected to report $0.52 for Q2 2024 Ping AN Insurance (Group) Co. of China, Ltd. ADR - Level I...
Epiroc AB ADR (EPOKY) is expected to report for Q3 2023 Sysmex Corporation ADR (SSMXY) is expected to report for Q2 2024 Streamline Health Solutions Inc. (STRM) is expected to report for Q1 2024 Helix Biopharma Corp. (HBPCF) is expected to report for Q2 2024 Standard Chartered plc...